ARCHIVES

FDA Softening Its Stance On CME Guidelines; New Version To Be More In Line with ACCME

This article is from The Cancer Letter archive.

Vol. 18 No. 14 | April 3, 1992

Download PDF Visit The Full Archive

Related Articles

Klausner Reaffirms NCI’s “No. 1 Priority” Is Funding investigator-Initiated Research

September 13, 1996

Shared Specimen Resource Needed, GYN Review Finds.

February 1, 2002

NCAB Asks NCI To Delay Proposed change In Breast Cancer Screening Guidelines

November 26, 1993

NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future

September 20, 1991

FDA Approves Two Oral Drugs For Metastatic Melanoma

June 28, 2013

Anti-Impoundment, Panel Stay In Cancer Renewal Act; Conferees Finally Agree On Research Training Bill

June 14, 1974